Chronic Hepatitis C and Direct Acting Antivirals

Maria Westerhoff, Joseph Ahn

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


The hepatitis C virus (HCV) is the most common blood-borne infection in the United States and is the most common cause of end-stage liver disease requiring liver transplant. Over the last 10 years, direct acting antiviral therapies have revolutionized HCV treatment, increasing the cure rates from less than 50% to more than 90% in those who reach access to care. This article is an overview for pathologists and clinicians covering the histologic findings of HCV as well as direct acting antiviral therapy.

Original languageEnglish (US)
Pages (from-to)287-296
Number of pages10
JournalSurgical Pathology Clinics
Issue number2
StatePublished - Jun 2018


  • Diagnostic criteria
  • Directly acting antivirals
  • Hepatitis C
  • Histology
  • Liver biopsy
  • Transient elastography

ASJC Scopus subject areas

  • Surgery
  • Pathology and Forensic Medicine


Dive into the research topics of 'Chronic Hepatitis C and Direct Acting Antivirals'. Together they form a unique fingerprint.

Cite this